Study Exclusion reasons Remarks Reference(s)
BCN PEP-CoV-2-Study 2 (Mitja Lancet-preprint), 2020 randomized controlled trial

Mitja O et al. Lancet preprint

Mohana, 2020 retrospective cohort (claims database) no control group

Mohana A Int J Infect Dis 2020 Oct 16;S1201-9712(20)32235-9. 10.1016/j.ijid.2020.10.031

Thakar, 2021 randomized controlled trial other chloroquine nasal drops

Thakar A Indian J Med Res 2021 Jan & Feb;153(1 & 2):151-158. 10.4103/ijmr.IJMR_3665_20

Kanran M, 2020 randomized controlled trial other randomization process unclear : Thepatients who did not give consent for treatment with HCQ or had a known allergy to HCQ orchloroquine or had another known contraindication to treatment with the study drug, includingretinopathy, G6PD deficiency and QT prolongation served as controls

sultan mehmood kamran medRxiv 10.1101/2020.07.30.20165365